Brad Bolzon, Ph.D., is Chairman and Managing Director of Versant. He is the leader of the firm, architect of its strategy, and oversees operations across North America and Europe.

Brad combines 13 years of global pharmaceutical industry leadership experience and 20 years as a venture capitalist. His track record consists of a multitude of successful investments including Amira, Okairos, Speedel, Quanticel, Novira, Flexion, Crispr, BioTie, Jecure, BlueRock, Black Diamond, Northern Biologics, Monte Rosa and the firm’s Discovery Engines that have collectively generated more than $2 billion in returns for Versant stakeholders. Over his tenure, he has translated that experience into building and developing the current Versant investment team.

• 

  Chairman of the Board in Versant Ventures

  HARNESSING THE POWER OF SCIENCE, GLOBALLY

• 

  Managing Director in Versant Ventures

  HARNESSING THE POWER OF SCIENCE, GLOBALLY